Background: The lifelong and remitting nature of ulcerative colitis results in considerable disability and a substantial negative impact on quality of life. The major goal of the therapy of ulcerative colitis is considered to be the modification of the course of the disease, so that the patient's quality of life can be improved while minimising disease-related disability. Although considerable progress in understanding the molecular pathways involved in ulcerative colitis has led to improved treatment options, there is currently no definitive cure for ulcerative colitis, there remain considerable unmet needs in terms of long-term efficacy and safety, and there are many patients who continue to be burdened by physical and psychological symptoms. Defining unmet needs can help to increase the awareness of the shortcomings of current therapeutic management and highlight the need to achieve not only a control of clinical symptoms but also control of mucosal healing, in order to attain the best possible long-term outcomes.
Methods: With the aim of providing a better understanding of the unmet needs of patients towards improving overall care, a Delphi process was used to obtain consensus among a group of Italian ulcerative colitis experts. The consensus group met with a major focus of delineating the unmet needs of current treatment strategies and overall management of ulcerative colitis, while also focusing on quality of life and patient care.
Results: Three main areas were identified: (i) treatment, (ii) monitoring and risk management, and (iii) patient-related issues. A high level of consensus was reached on all but one of the statements identified.
Conclusions: The findings arising from the Delphi process provide valuable insights into the unmet needs in the management of moderate-to-severe ulcerative colitis from the clinician's perspective, while emphasising the benefits of therapeutic individualization and suggesting areas that need additional study with the aim of optimising the treatment of patients with ulcerative colitis.
Copyright © 2019 Marco Daperno et al.
Conflict of interest statement
Giuseppina Liguori is a Pfizer employee. All the other authors declare no conflict of interest.
Unmet Medical Needs in Ulcerative Colitis: An Expert Group ConsensusS Danese et al. Dig Dis 37 (4), 266-283. PMID 30726845. - Meta-AnalysisThese expert group meetings found a number of areas of unmet needs in UC, which is an important first step in tackling them in the future. Future research and development …
Defining Endoscopic Response and Remission in Ulcerative Colitis Clinical Trials: An International ConsensusL Vuitton et al. Aliment Pharmacol Ther 45 (6), 801-813. PMID 28112419. - ReviewThese international recommendations represent the first consensus on measurement indices for endoscopic outcomes in ulcerative colitis. They should be subject to prospect …
Generalized Pyoderma Gangrenosum Associated With Ulcerative Colitis: Successful Treatment With Infliximab and AzathioprineF Chatzinasiou et al. Acta Dermatovenerol Croat 24 (1), 83-5. PMID 27149138. - Case ReportsPyoderma gangrenosum (PG) is a rare ulcerative skin disease, part of the spectrum of neutrophilic and auto-inflammatory dermatoses. Its pathogenesis is unknown, although …
Review Article: Acute Severe Ulcerative Colitis - Evidence-Based Consensus StatementsJH Chen et al. Aliment Pharmacol Ther 44 (2), 127-44. PMID 27226344. - ReviewThese evidenced-based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up-to-date best practice recommendations th …
Review Article: Evolving Concepts in Treatment and Disease Modification in Ulcerative ColitisSB Hanauer. Aliment Pharmacol Ther 27 Suppl 1, 15-21. PMID 18307645. - ReviewDisease modification is increasingly becoming a treatment goal in the management of ulcerative colitis. However, long-term studies are needed to examine further the disea …